Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.

Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P.

Br J Cancer. 2008 Aug 5;99(3):448-54. doi: 10.1038/sj.bjc.6604497.

2.

Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.

Kappers MH, van Esch JH, Smedts FM, de Krijger RR, Eechoute K, Mathijssen RH, Sleijfer S, Leijten F, Danser AH, van den Meiracker AH, Visser TJ.

J Clin Endocrinol Metab. 2011 Oct;96(10):3087-94. doi: 10.1210/jc.2011-1172. Epub 2011 Aug 3.

PMID:
21816788
3.

Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?

Tassi R, Baldazzi V, Lapini A, Carini M, Mazzanti R.

Clin Genitourin Cancer. 2015 Apr;13(2):e101-5. doi: 10.1016/j.clgc.2014.08.009. Epub 2014 Sep 22.

PMID:
25450040
4.

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM.

J Natl Cancer Inst. 2007 Jan 3;99(1):81-3.

PMID:
17202116
5.

Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.

Kitajima K, Takahashi S, Maeda T, Yoshikawa T, Ohno Y, Fujii M, Miyake H, Fujisawa M, Sugimura K.

Eur J Radiol. 2012 Sep;81(9):2060-5. doi: 10.1016/j.ejrad.2011.06.035. Epub 2011 Jul 2.

PMID:
21724350
6.

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK.

Ann Intern Med. 2006 Nov 7;145(9):660-4.

PMID:
17088579
7.

[Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].

Fuertes Zamorano N, De Miguel Novoa MP, Molino González A, Díaz Pérez JÁ, Rojas-Marcos PM, Montañez Zorrilla MC.

Endocrinol Nutr. 2010 Dec;57(10):486-91. doi: 10.1016/j.endonu.2010.06.002. Epub 2010 Aug 10. Spanish.

PMID:
20702151
8.

The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.

Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M, Mazzanti R.

Urol Oncol. 2012 Sep;30(5):704-10. doi: 10.1016/j.urolonc.2010.07.015. Epub 2010 Oct 2.

PMID:
20884255
9.

Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer.

Del Fabbro E, Dev R, Cabanillas ME, Busaidy NL, Rodriguez EC, Bruera E.

J Chemother. 2012 Aug;24(4):221-5. doi: 10.1179/1973947812Y.0000000022.

10.

[Treatment with sunitinib and hypothyroidism--a case report and overview of literature].

Kreze A Jr, Stáhalová V, Zadrazilová A, Koskuba J, Kosák M.

Klin Onkol. 2009;22(4):176-8. Slovak.

PMID:
19731880
11.

Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

Feldman DR, Martorella AJ, Robbins RJ, Motzer RJ.

J Natl Cancer Inst. 2007 Jun 20;99(12):974-5; author reply 976-7. Epub 2007 Jun 12. No abstract available.

PMID:
17565156
12.
13.

Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.

Buda-Nowak A, Kucharz J, Dumnicka P, Kuzniewski M, Herman RM, Zygulska AL, Kusnierz-Cabala B.

Med Oncol. 2017 Apr;34(4):68. doi: 10.1007/s12032-017-0928-z. Epub 2017 Mar 25.

14.

Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?

Rogiers A, Wolter P, Op de Beeck K, Thijs M, Decallonne B, Schöffski P.

Thyroid. 2010 Mar;20(3):317-22. doi: 10.1089/thy.2009.0125.

PMID:
20144039
15.

Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?

Sella A, Hercbergs AH, Hanovich E, Kovel S.

Chemotherapy. 2012;58(3):200-5. doi: 10.1159/000337079. Epub 2012 Jun 29.

PMID:
22759787
16.

The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma.

Shinohara N, Takahashi M, Kamishima T, Ikushima H, Otsuka N, Ishizu A, Shimizu C, Kanayama H, Nonomura K.

Br J Cancer. 2011 Jan 18;104(2):241-7. doi: 10.1038/sj.bjc.6606029. Epub 2010 Dec 14.

17.

Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?

Pani F, Atzori F, Baghino G, Boi F, Tanca L, Ionta MT, Mariotti S.

Thyroid. 2015 Nov;25(11):1255-61. doi: 10.1089/thy.2015.0170. Epub 2015 Oct 14.

PMID:
26414109
18.

Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

Grossmann M, Premaratne E, Desai J, Davis ID.

Clin Endocrinol (Oxf). 2008 Oct;69(4):669-72. doi: 10.1111/j.1365-2265.2008.03253.x. Epub 2008 Apr 3.

PMID:
18394019
19.

Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.

Sato S, Muraishi K, Tani J, Sasaki Y, Tokubuchi I, Tajiri Y, Yamada K, Suekane S, Miyajima J, Matsuoka K, Hiromatsu Y.

Endocr J. 2010;57(10):873-80. Epub 2010 Aug 21.

20.

Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.

Theou-Anton N, Faivre S, Dreyer C, Raymond E.

Drug Saf. 2009;32(9):717-34. doi: 10.2165/00002018-200932090-00003. Review.

PMID:
19670913

Supplemental Content

Support Center